This paper describes the development and implementation of training programs for primary care medical practitioners and pharmacists in the delivery of buprenorphine and LAAM treatment in the management of opiate dependence. Separate training programs were developed for each medication. Each training package included learning objectives, training materials, and assessment instruments. Findings of the evaluation of these initiatives and the subsequent Australian postregistration training program for buprenorphine are described.
WardJ, MattickRP and HallW, eds. 1998. Methadone Maintenance Treatment and Other Opioid Replacement Therapies, Amsterdam: Harwood Academic Publishers.
2.
Commonwealth Department of Human Services and Health. 1995. Review of Methadone Treatment in Australia, Canberra: Commonwealth Department of Human Services and Health.
3.
LintzerisN, KoutroulisG, OdgersP, EzardN, LanaganA, MuhleisenP and StoweA. 1996. Report on the Evaluation of Community Methadone Services in Victoria, Fitzroy, Victoria: Turning Point Alcohol & Drug Centre.
4.
DrummerO, OpeskinK, SyrjanenM and CordnerS. 1992. Methadone toxicity causing death in ten subjects starting on a methadone maintenance program. Am J Forensic Med Pathol, 13: 346–350.
5.
LintzerisN and WatersL.Teaching the fundamentals of methadone prescribing to General Practitioners In Victoria. National Methadone Conference. 1994, Sydney, Australia.
6.
Departmentof. 1995. Health and Community Services: Victorian Methadone Program. Guidelines for Providers, Melbourne: Victorian Government Department of Health and Community Services.
7.
KutinJ and LintzerisN. 1997. “Introduction and background to the feasibility research”. In Expanding Treatment Options for Heroin Dependence in Victoria: Buprenorphine, LAAM, Naltrexone and Slow–Release Oral Morphine, New Pharmacotherapies Project—Feasibility Phase Edited by: RitterA, KutinJ, LintzerisN and BammerG. Fitzroy, Victoria: Turning Point Alcohol and Drug Centre.
8.
BerbatisC, SvmderlandV, BulsaraM and LintzerisN. 2000. Tiends in licit opioid use in Australia, 1984–1998: Comparative analysis of international and jurisdictional data. Med J Aust, 173: 524–527.
9.
EzardN, LintzerisN, OdgersP, KoutroulisG and MuhleisenP. 1999. An evaluation of community methadone services in Victoria, Australia: Results of a client survey. Drug Alcohol Rev, 18: 417–423.
10.
ThomsonN and MorganK. 1999. Victorian Community Methadone Program: An Investigation Into Consumer Complaints and Grievances, Melbourne: VIVAIDS.
11.
LingW, RawsonRA and ComptonMA. 1994. Substitution pharmacotherapies for opioid addiction: From methadone to LAAM and buprenorphine. J Psychoactive Drugs, 26: 119–128.
12.
MattickRP, OliphantD, WardJ and HallW. 1998. “The effectiveness of other opioid replacement therapies: LAAM, heroin, buprenorphine, naltrexone and injectable maintenance”. In Methadone Maintenance Treatment and Other Opioid Replacement Therapies, Edited by: WardJE, Mattick and RichardP. Amsterdam, Netherlands: Harwood Academic Publishers.
13.
Premier's Drug Advisory Council. 1996. Drugs and Our Community, Melbourne: Victorian Government.
14.
AuriacombeM, FranquesP, DaulouedeJP and TignolJ. 1999. The French experience: Results from extensive delimited research studies and nation–wide sample surveys. Res Clin Forums, 21: 9–16.
15.
RitterA, KutinJ, LintzerisN and BammerG. 1997. “New Pharmacotherapies Project—Feasibility Phase”. In Expanding Treatment Options for Heroin Dependence in Victoria: Buprenorphine, LAAM, Naltrexone and Slow–Release Oral Morphine, Fitzroy, Victoria: Turning Point Alcohol and Drug Centre.
16.
AllsopS, BellJ, BroughR, DwyerP, EdmondsC, LintzerisN and MohindraV. 1997. Learning Objectives for Methadone Prescribers, Canberra: Australian Government Publishing Service.
17.
LintzerisN, ClarkN, MuhleisenP, RitterA, AliR, BellJ, GowingL, HawkinL, Henry EdwardsSS, MattickRP, MoheitB, NewtonI, QuigleyA, WhickerS and WhiteJ. 2001. National Clinical Guidelines and Procedures for the Use of Buprenorphine in the Treatment of Heroin Dependence, Canberra: Australian Government Publishing Service.
18.
Center for Substance Abuse Treatment. 1995. LAAM in the Treatment of Opiate Addiction, Rockville, MD: US. Department of Health and Human Services.
19.
NewbleD, DawsonB, DauphineeD, PageG, MacdonaldM, SwansonD, MulhollandH, ThomsonA and Van der Veuten. 1994. Guidelines for Assessing Clinical Competence. Teaching Learn Med, 6: 213–220.
20.
PageG, BordageG and AllenTi. 1995. Developing Key–feature Problems and Examinations to Assess Clinical Decision–making Skills. Acad Med, 70: 194–201.
21.
LintzerisN, ConnollyK and MuhleisenP. 2001. Subutex® Training Package, London: Wells Medical Group.
22.
ClarkN, RitterA, LintzerisN, KutinJ and BammerG. 2001. LAAM treatment in primary care settings: Results of a randomised controlled trial. Drug Alcohol Depend, 63: S28
23.
RitterA, LintzerisN, ClarkN, KutinJ and BammerG. 2001. A randomised trial of buprenorphine maintenance in primary care office–based settings: Clinical guidelines, training programs and efficacy. Drug Alcohol Depend, 63: S131
24.
HainesA, FreemantleN, WattI and LugonM. 1996. “Increasing the effectiveness of clinical intervention”. In Effective Clinical Practice, Edited by: MilesA and LugonM. Oxford: Blackwell Science.
